Urinary Tract Infections
Conditions
Keywords
UTI
Brief summary
Safety and efficacy of Cipro XR in a naturalistic setting and the effectiveness of an educational brochure. - Women with urinary tract infections were treated with Cipro XR. They were also given a brochure with information about urinary tract infections and later tested on the information.
Interventions
BEHAVIORALCipro XR (Ciprofloxacin, BAYQ3939)
Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
Sponsors
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Ambulatory women outpatients 18 to 65 years of age with a documented clinical diagnosis of uUTI characterized by dysuria with either urgency or frequency. Women of childbearing age were enrolled only if they were highly unlikely to conceive during the study and were practicing a suitable method of birth control or were at least 1 year postmenopausal. * Positive leukocyte esterase (\>/= 1+) and positive nitrite test using a urine dipstick method of analysis. * Willing to give written consent.
Exclusion criteria
* Pregnant or nursing * Complicated UTI * Allergy to Cipro XR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the effect on knowledge of uncomplicated urinary tract infection (uUTI) in patients who were given a disease-directed educational brochure to read versus patients who were not given the brochure. | 3-10 days after start of therapy |
Secondary
| Measure | Time frame |
|---|---|
| To examine the difference between physician and patient perceptions of the symptoms of uUTI. | At baseline visit pre-therapy |
| To collect data on the clinical efficacy and safety of Cipro XR, 500 mg, PO once daily, for 3 days, in the treatment of uUTI in a naturalistic setting. | 1-3 days after end of therapy for efficacy and up to 30 days for safety |
Outcome results
None listed